Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Co-medication with metformin or statins did not impact survival in ovarian cancer patients. However, beta blocker use was linked to worse survival, though the reason remains unclear.
Area Of Science
- Oncology
- Pharmacology
- Clinical Trials
Background
- Ovarian cancer patients often have comorbidities requiring co-medications.
- The impact of common co-medications like metformin, statins, and beta blockers on ovarian cancer survival is not well-established.
Purpose Of The Study
- To investigate the association between co-medication with metformin, statins, or beta blockers and survival outcomes in primary ovarian cancer patients.
Main Methods
- Pooled data from four clinical trials (AGO-OVAR 11, 12, 15, 16) involving 2857 ovarian cancer patients.
- Patients were categorized as 'ever users' or 'never users' of specific co-medications.
- Multivariate Cox regression analyses adjusted for confounders were used to assess survival impacts.
Main Results
- Co-medication with metformin (n=100) or statins (n=226) showed no significant impact on progression-free survival (PFS) or overall survival (OS).
- Co-medication with selective beta blockers (n=391) was significantly associated with a higher risk of recurrence and death (PFS HR 1.22, OS HR 1.25).
- Ever users of co-medications were older, more obese, and had higher comorbidity scores.
Conclusions
- Metformin and statin co-medication do not appear to significantly affect survival in primary ovarian cancer.
- Selective beta blocker use is associated with worse survival outcomes in ovarian cancer patients.
- Further research is needed to determine if the observed association with beta blockers is due to the drug's effect on tumor biology or underlying patient conditions.
Keywords:
Ovarian Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...